More than 60 years ago, Otto Warburg said that cancer cells differ from normal cells in the metabolic pathway they use for the oxidation of sugar.

Rather than the typical series of oxidative steps that take place in the citric acid cycle, cancer cells metabolize sugar via the glycolytic pathway irrespective of whether oxygen is present or not.

Writing in a new paper for The EMBO Journal, researchers believe that the reason for this difference in colon cancer is changes in the Wnt signaling pathway, an essential communication pathway operating in these tumors.

3 million men across America experience infertility. Today, researchers described a key event during sperm development that is essential for male fertility - a protein controls DNA packaging to protect a man's genetic information. 

Psychologists probably won't like the implication that e-cigarettes cause mental illness, or vice versa, but in the topsy-turvy world of the American culture wars, where vaccines are bad and inhaling marijuana smoke is good, all fields are going to take their lumps.

E-cigarettes should be healthier for people - there is no smoke and smoking is what causes 10 percent of lung cancer - but there is definitely a concerted effort to undermine them. A new pape in Tobacco Control, for example, warns us that the FDA has not approved e-cigarettes as a cessation aid. It doesn't mean they are harmful or homeopathy but that is how the issue is framed. And in science and health, framing is always bad.

A shared population of methicillin-resistant Staphylococcus aureus (MRSA) bacteria circulates both in humans and companion animals, according to a study published this week in mBio®, the online open-access journal of the American Society for Microbiology.

Researchers at Children's Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the potential for a future treatment for patients who would otherwise experience relapse of their disease.

Nora Heisterkamp, PhD, and colleagues at The Saban Research Institute of Children's Hospital Los Angeles have discovered that by targeting the B-cell activating receptor (BAFF-R), chemotherapy-resistant precursor B acute lymphoblastic leukemia cells (pre-B ALL) can be selectively killed in vivo and in vitro. Results will be published on May 13 in Molecular Cancer Therapeutics.